Intellia Therapeutics (NTLA) PT Raised to $85 at Chardan Capital Markets

February 10, 2021 9:39 AM EST
Get Alerts NTLA Hot Sheet
Price: $66.56 -1.14%

Rating Summary:
    13 Buy, 4 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 6 | Down: 16 | New: 67
Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Chardan Capital Markets analyst Geulah Livshits raised the price target on Intellia Therapeutics (NASDAQ: NTLA) to $85.00 (from $57.50) while maintaining a Buy rating.

The analyst commented, "After a strong 4Q20, we see scope for 2021 performance on (1) anticipated guidance around initial NTLA-2001 data in hATTR-PN, (2) 2 IND filings (or equivalent) in HAE and AML, (3) visibility on the company's allogeneic ex vivo strategy, and (4) pipeline expansion. As discussed in our 11 January 2021 preview, Intellia's initiation of dosing the 1st systemic CRISPR therapy was an important milestone for the space and to us, a signal of regulators' growing comfort with in vivo gene editing. We now update our model to reflect Intellia's progress towards the clinic as well as growing validation for gene editing platforms more broadly, based on factors initially outlined in our Chardan Gene Editing Framework"



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Chardan Capital Markets